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Abstract Biallelic inactivation of the ATM gene causes
ataxia–telangiectasia (A–T), a complex neurological
disease associated with a high risk of leukaemias and lym-
phomas. Mothers of A–T children, obligate ATM hetero-
zygote mutation carriers, have a breast cancer (BC) relative
risk of about 3. The frequency of ATM carriers in BC women
with a BC family history has been estimated to be 2.70%. To
further our clinical understanding of familial BC and
examine whether haematological malignancies are predic-
tive of ATM germline mutation, we estimated the frequency
of heterozygote mutation carriers in a series of 122 BC
women with a family history of both BC and haematological
malignancy and without BRCA1/2 mutation. The gene
screening was performed with a new high throughput
method, EMMA (enhanced mismatch mutation analysis).
Amongst 28 different ATM variants, eight mutations have
been identified in eight patients: two mutations leading to a
putative truncated protein and six being likely deleterious
mutations. One of the truncating mutations was initially
interpreted as a missense mutation, p.Asp2597Tyr, but is
actually a splice mutation (c.7789G[T/p.Asp2597_Lys
2643[LysfsX3). The estimated frequency of ATM hetero-
zygote mutation carriers in our series is 6.56% (95% CI:
2.16–10.95), a significantly higher figure than that observed
in the general population, estimated to be between 0.3 and
0.6%. Although a trend towards an increased frequency of
ATM carriers was observed, it was not different from that
observed in a population of familial BC women not selected
for haematological malignancy as the frequency of ATM
carriers was 2.70%, a value situated in the confidence
interval of our study.
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Introduction
Breast cancer (BC) is the most common cancer in western
countries. Most cases of BC are sporadic, but almost 13%
of women have at least one first-degree relative with BC
[1]. The BRCA1 and BRCA2 genes are the two genes
whose germline monoallelic inactivating mutations are
identified in 15–20% of women with BC and a strong
family history of BC [2], suggesting the presence of other
BC predisposing genes explaining at least a portion of the
remaining non-mutated familial cases. Three other genes
are associated with an increased BC risk: TP53, STK11,
and PTEN. As mutations of these genes are associated
with rare autosomal dominant syndromes, these genes
must be considered in a specific familial context. They
also have a very small contribution to familial aggrega-
tions (\1% of familial cases) [2]. The ATM gene (ataxia
telangiectasia mutated) encodes a lipid kinase phosphati-
dylinositol 3-kinase (PI3K) expressed in a wide range of
tissues. It is the apex of a signalling cascade that detects
and repairs DNA double-strand breaks, a cascade in which
the BRCA1 and BRCA2 proteins are involved [3, 4].
Biallelic inactivation of the ATM gene causes ataxia–tel-
angiectasia (A–T), a neurodegenerative disorder that
develops in early childhood. Ataxia–telangiectasia chil-
dren present a severe clinical phenotype characterised by
progressive cerebellar ataxia and dysarthria, associated
with ocular telangiectasia, immunodeficiency, sensitivity
to ionising radiation, and an increased risk of cancers,
especially leukaemias and lymphomas [5]. A large number
of ATM mutations have been identified, extending over a
very long 10 kb coding sequence scattered in 62 exons.
Point or small size mutations and large gene rearrange-
ments have been identified and some deleterious missense
mutations located in the PI3K domain have been reported
(ATM mutation database: http://chromium.liacs.nl/LOVD2/
home.php) [6, 7].
The mothers of A–T children, obligate ATM heterozy-
gote mutation carriers, have been shown to present an
increased BC risk [8]. Additional studies conducted in
families of A–T children have shown a relative risk (RR) of
about three attributable to ATM heterozygosity in women
[9–12]. Various BC population studies have tried to esti-
mate the risk of developing BC amongst ATM mutation
carriers, sometimes with controversial results, as reviewed
in Ahmed and Rahman [13]. In a more recent study,
Renwick et al. analysed 443 cases of familial BC and 521
controls, and found 12 women carrying an ATM mutation
in the case group (2.70%) and two in the control group
(0.38%) [14]. They estimated that ATM mutation hetero-
zygosity was associated with a BC RR of 2.37 (95% CI:
1.51–3.78) [14]. As the rate of BRCA1/2 mutation detection
in BC women with a family history of BC is 15–20%, the
rate of ATM mutations is five to seven times lower than the
rate of BRCA1/2 mutations.
ATM mutations are involved in the development of
lymphoid malignancies as A–T patients are at high risk of
T-cell acute lymphocytic leukaemia (T-ALL) and espe-
cially prolymphocytic leukaemia (T-PLL) [15]. Somatic
inactivation of the ATM gene has been reported in T-PLL
and B-cell chronic lymphocytic leukaemia (B-CLL)
occurring in patients outside an A–T context [16–18].
Mutations observed in these reports are essentially mis-
sense mutations and mostly occur in the PI3 K domain.
Monoallelic ATM germline mutations have also been
reported in some patients with B-CLL, mantle cell lym-
phoma (MCL), and T-cell ALL [19–22]. In Stankovic’s
series, 18% of patients were carriers of a monoallelic ATM
germline mutation [19]. In a short series of T-ALL
affected children, a monoallelic ATM germline mutation
was identified in 20% of cases [23]. In a Nordic study of
relatives of A–T children, an increased standardised
incidence ratio (SIR) of 37 (95% CI: 13–80) was observed
for leukaemias and non-Hodgkin lymphomas [11]. A trend
towards an increased RR of leukaemias and lymphomas
was also observed in a French study of the relatives of
A–T children [24].
To further our clinical understanding of familial BC
without BRCA1/2 mutation and to limit the volume of ATM
gene screening, we estimated the frequency of ATM
mutation carriers in BC women with a family history of
both BC and haematological malignancy. In other words,
this study was designed to examine whether the presence of
leukaemia and/or lymphoma amongst relatives in BC
families was a predictive factor for ATM mutation. A
second objective was to report a new high throughput
method, called enhanced mismatch mutation analysis
(EMMA), that we have adapted for ATM gene mutation
screening. We report the results of EMMA ATM gene
analysis in a series of 122 unrelated BRCA1 and BRCA2
mutation negative women with at least one-first or second
degree relative with leukaemia or lymphoma.
Patients and methods
Patients
Between January 1995 and December 2005, 2,009 unre-
lated patients with BC (index case) were tested for BRCA1
and BRCA2 mutations at the Institut Curie. They had a
family history of breast and/or ovarian cancer and/or
developed BC before the age of 36. A family history was
defined as either two first-degree relatives with cancer: (1)
at least one with invasive BC before the age of 41, or (2)
one with ovarian cancer or breast cancer at any age, or
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three first-degree or second degree relatives from the same
lineage with invasive BC or ovarian cancer at any age,
where the index case constituted one of the cases. Amongst
the 1,629 patients with negative BRCA1 and BRCA2
screening, 122 had at least one-first or second degree rel-
ative with leukaemia or lymphoma, and this relative
belonged to the branch of the family in which breast can-
cers were segregating. Informed consent for breast cancer
genetic studies was obtained from each woman at the
family cancer clinic.
DNA preparation
Two DNA extraction methods from whole blood were used:
(1) a modified perchlorate/chloroform procedure [25], or (2)
a rapid method using the NucleoSpin Blood extraction kit
(Macherey–Nagel; ref. http://www.mn-net.com). DNA
concentrations and the quality of each sample were deter-
mined spectrophotometrically at 260/280 nm (NanoDrop
ND-1000, NanoDrop technologies).
EMMA
The enhanced mismatch mutation analysis, EMMA (Flui-
gent, France), is a method of mutation screening based on
heteroduplex analysis (HDA). Heteroduplexes and homo-
duplexes are separated by their different electrophoretic
mobility due to their conformational differences. The reso-
lution of EMMA is considerably better than that of standard
HDA due to a combination of high resolution block-
copolymer sieving matrix, and nucleosides as additives in
the electrophoretic medium [26, 27]. The medium was loa-
ded on the ABI3130XL sequencing system (Applied Bio-
systems 2006). EMMA also allows simultaneous analysis of
numerous amplicons by multiplex analysis. This method
allows the simultaneous detection of both small mutations
and large gene rearrangements (LGR) by applying semi-
quantitative PCR conditions and an external control ampli-
con [28]. As a result of multiplex analysis and LGR
detection, EMMA is a high throughput screening mutation
method. Data analysis was performed with Emmalys
software (Fluigent, France) for both point and small muta-
tions and Excel Visual Basic macro for LGR analysis.
Amplicon and multiplex design
Primers were designed using the web-based Primer3 soft-
ware (http://frodo.wi.mit.edu/cgi-bin/primer3/primer3_www.
cgi) to cover the 62 coding exons of the ATM gene and the
splice site junctions. A series of 36 multiplexes of 2–4
amplicons, including the external gene control, was pre-
pared. Amplicon sizes ranged between 217 and 567 bp
(basepair). In a given multiplex, the length difference
between two adjacent amplicons was at least 50 bp. Primer
sequences and multiplex amplicon PCR conditions are
reported in Table S1 (supplementary data).
EMMA PCR conditions
PCR conditions were identical for all multiplexes. About
100 ng of DNA were amplified using Taq ABgene 0.06 U/
ll (ABgene UK, ref: www.abgene.com), 5 mM MgCl2,
4 9 0.2 mM dNTPs, and 0.08–0.3 lM of each primer in a
final reaction volume of 20 ll. Cycling conditions were as
follows: 94C for 5 min, followed by 25 cycles of 94C for
30 s, 58C for 30 s, and 72C for 30 s, followed by two
steps of 72C for 7 min and 98C for 10 min. Heteroduplex
formation consisted of 73 cycles of 98C for 30 s, with
temperature decreasing by 1 at each cycle, and a final step
at 25C for 10 min.
DNAs for EMMA validation study
As small insertions or deletions have been shown to be
easily detected by EMMA, we focused our validation study
on nucleotide substitutions previously detected by direct
sequence analysis [27]. DNAs from A–T children or their
ATM heterozygote carrier relatives, previously referred to
our laboratory, were selected for nucleotide substitutions.
DNAs carrying a substitution were available for 49
amplicons. The substitutions studied are reported in Table
S2 (supplementary data).
A heterozygote ATM deletion from exons 26–65 was
also used to validate LGR detection. An amplicon con-
taining exon 8 or 11 of the RB1 gene was used as external
control [29]. DNAs from these A–T patients were used as
experimental controls in the study of the 122 BC patients.
Sequencing of EMMA variant profiles
Each DNA corresponding to a different EMMA profile as
compared with the majority of profiles was sequenced.
100 ng of DNAs were amplified using Taq ABgene
0.025 U/ll (ABgene UK, ref: www.abgene.com), 4 9
0.2 mM dNTPs, 1.5 mM MgCl2, and 0.3 lM of each pri-
mer in a final reaction volume of 50 ll. Amplification was
performed with a touchdown PCR protocol consisting of an
initial denaturation step at 94C for 5 min followed by 35
PCR cycles: denaturation at 94C for 30 s, annealing for
30 s with temperature gradually decreasing from 60C to
52C for 35 cycles, and elongation at 72C for 30 s.
PCR products were separated by agarose gel electro-
phoresis, purified (Macherey Nagel), and sequenced, using
one of the PCR primers (usually the forward primer, except
in the case of poor sequence quality), Big Dye Cycle
Sequencing Reactions and an ABI3130XL automated
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Fig. 1 Emma analysis of the multiplex amplified ATM exons 24, 28,
and RB1 exon 8. a The profiles of 93 EMMA analysed DNAs were
superimposed with Emmalys software. Each peak corresponds to a
single amplified exon or amplicon. Fragment 1 is ATM exon 24. Two
profiles were identified: (1) a single peak profile detected in 90 DNAs,
and (2) a triple peak profile detected in three DNAs with a
heterozygous c.3161C[G/p.Pro1054Arg polymorphism. Fragment 2
is RB1 exon 8, used as external control for LGR detection. Only one
peak profile was detected. Fragment 3 is ATM exon 28. Two profiles
were identified: (1) a single peak profile detected in 92 DNAs, and (2)
a double peak profile detected in 1 DNA with the heterozygous
IVS28, c.3993?40G[A variant. b Individual DNA profiles of ATM
24 and 28 amplicons obtained with Emmalys software. Regarding
exon 24, 5 DNAs lead to a normal profile (2a–6a). The 1a profile has
three peaks and corresponds to the superimposition of the c.3161C/
p.Pro1054 and the c.3161G/p.Arg1054 alleles. Regarding exon 28, 5
DNAs lead to a normal profile (1b, 3b–6b). The 2b profile has two
peaks and corresponds to the superimposition of the IVS28,
c.3993?40G and IVS28, c.3993?40A alleles
446 Breast Cancer Res Treat (2010) 119:443–452
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sequencer (Applied Biosystems). Seqscape (Applied
Biosystems) software was used for sequence analysis.
The ATM coding sequence reference is U33841. The
first translated nucleotide is the reference nucleotide.
Control DNAs for analysing the population frequency
of sequence variants identified in the 122 BC cases
The frequency of DNA variants detected in the series of
122 BC women was determined in a series of 93–186
unrelated controls. Controls were children tested for RB1
gene mutation due to the presence of retinoblastoma, a
disease unrelated to the ATM gene and for which our lab-
oratory routinely performs mutation screening.
The arbitrary threshold of 1% was selected according to
the definition of polymorphism in population genetics: a
DNA variant with a frequency of 1% or above was rather
considered with no functional effect.
Splice site score predictions
The genomic sequence environment of a DNA variant was
analysed using Splice Site Prediction by Neural Network
(NNSPLICE available at http://www.fruitfly.org/seq_tools/
splice.html), Splice Site Finder (SSF available at http://
violin.genet.sickkids.on.ca/*ali/splicesitefinder.html), Max
EntScan (MES available at http://genes.mit.edu/burgelab/
maxent/Xmaxentscan_scoreseq.html) [30].
Protein conservation and A-GVGD score
The A-GVGD algorithm developed by Tavtigian et al. for
the analysis of various genes, including the ATM gene, was
used to contribute to discriminate disease-causing missense
mutations from neutral changes (http://agvgd.iarc.fr/) [31,
32]. This algorithm combines the biophysical characteris-
tics of amino acid changes (GV) and alignments of protein
Table 1 ATM germline variants and their characteristics in 122 BC patients with a family history of breast and haemotological malignancy
Nucleotide
change
Amino acid
change
Exon/
IVS
Freq. in
patients
Freq. in
controls
FAT or PI3K
domain
GV
score
GD
score
A-GVGD combined
score and prediction
Signification
proposed
c.4852C[T p.Arg1618X exon 34 1/122 0/186 – – – – Deleterious
c.7789G[T p.Asp2597_Lys2643
[LysfsX3
exon 55 1/122 0/186 – – – – Deleterious
c.749G[A p.Arg250Gln exon 9 1/122 0/186 – 0.00 42.81 C35 Likely deleterious
c.6067G[A p.Gly2023Arg exon 43 1/122 1/186 FAT 0.00 125.13 C65 Likely deleterious
c.7187C[G p.Thr2396Ser exon 51 1/122 0/93 FAT 111.69 6.18 C0 Likely deleterious
c.7305C[G p.Asn2435Lys exon 51 1/122 0/93 FAT 0.00 93.88 C65 Likely deleterious
c.8560C[T p.Arg2854Cys exon 60 1/122 0/93 PI3K 42.81 154.23 C35 Likely deleterious
c.9023G[A p.Arg3008His exon 65 1/122 0/186 PI3K 0.00 28.82 C25 Likely deleterious
c.1952T[C p.Leu651Pro exon 15 1/122 4/186 – 0.00 97.78 C65 Unknown
c.2119T[C p.Ser707Pro exon 15 3/122 0/186 – 73.35 0.00 C0 Unknown
c.2254C[G p.Leu752Val exon 17 1/122 0/186 – 0.00 30.92 C25 Unknown
c.2289T[A p.Phe763Leu exon 17 2/122 0/186 – 157.56 0.00 C0 Unknown
c.2476A[C p.Ile826Leu exon 19 1/122 0/186 – 141.80 4.86 C0 Unknown
c.4556T[C p.Val1519Ala exon 32 1/122 8/186 – 0.00 65.28 C65 Unknown
c.4802G[A p.Ser1601Asn exon 34 1/122 0/186 – 115.58 0.00 C0 Unknown
c.4975A[G p.Ile1659Val exon 35 1/122 0/93 – 93.66 0.00 C0 Unknown
c.5018G[C p.Ser1673Thr exon 36 1/122 0/186 – 111.49 0.00 C0 Unknown
c.6844A[C p.Asn2282His exon 49 1/122 1/186 FAT 64.77 36.57 C0 Unknown
c.6919C[T p.Leu2307Phe exon 49 1/122 1/186 FAT 0.00 21.82 C15 Unknown
c.1899-24A[G – IVS14 1/122 0/186 – – – – Unknown
c.3993?40G[A – IVS28 1/122 0/186 – – – – Unknown
c.4237-54T[C – IVS30 4/122 1/186 – – – – Unknown
c.4437-7A[C – IVS31 1/122 0/186 – – – – Unknown
c.6807?39C[T – IVS48 2/122 0/185 – – – – Unknown
c.7516-32T[G – IVS52 1/122 0/93 – – – – Unknown
c.7927?69T[C – IVS55 1/122 0/186 – – – – Unknown
c.3342G[A p.Lys1114Lys exon 25 1/122 1/149 – – – – Unknown
c.685C[T p.Leu229Leu exon 9 1/122 5/186 – – – – Likely neutral
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sequences of different and phylogenetically distant species
(GD), from human to zebrafish. The output from Align-
GVGD is an ordered series of grades ranging from C65
(most likely deleterious) to C0 (most likely neutral). Mis-
sense mutations with a score below C15 are considered as
probably neutral. When the score is at or above C15 and
below C35, missense mutations remain unclassified, at or
above C35 they are likely deleterious [32].
Results
EMMA validation for the ATM gene study
All of the 49 nucleotide substitutions located in 49 different
amplicons of the ATM gene and selected regardless of their
biological significance were detected (Fig. 1 and data not
shown, see supplementary data for the list of mutations
studied, Table S2). The deletion of exons 26–65 was
detected in all corresponding amplicons.
EMMA analysis in the series of 122 women
with familial BC and one relative
with haematological malignancy
A total of 28 different monoallelic sequence variants were
identified in 35 of the 122 BC women screened for ATM
gene mutation. These variants were initially interpreted as
follows: 1 nonsense mutation, 18 missense mutations, 2
silent mutations, 7 intronic variants (Table 1). No LGR
was detected.
Twenty-two heterozygous polymorphisms were also
detected and were classified as polymorphisms on the basis
of previous reports in the literature, in databases, especially
the NCBI SNP database, or in A–T patients studied in our
laboratory (data not shown) (Table 2).
A nonsense mutation: c.4852C[T/p.Arg1618X was
identified in one patient. This mutation, leading to a
putative truncated and non-functional protein was consid-
ered to be deleterious.
The biological function of the 18 missense mutations
identified was unknown, as they have not been previously
reported as deleterious in databases. The following five
criteria were used to assess the significance of their func-
tional effect: (1) a carrier frequency \1% in a series of
controls, (2) identification of the missense mutation in an
A–T child carrying no more than one deleterious ATM
mutation, (3) location in an ATM protein domain known to
be functionally important, especially the PIK3 and FAT
domains, (4) the importance of the amino acid (aa) change
and aa species conservation analysed by the A-GVGD
algorithm, and (5) a putative splice effect by using in silico
splice site score prediction models. These criteria are listed
in order of increasing relevance with respect to a putative
deleterious effect.
In one case, a splicing defect was suspected on in silico
analyses, as the c.7789G[T mutation, initially interpreted
as p.Asp2597Tyr, is actually a splicing mutation. c.7789G
is the first nucleotide of exon 55. The G [ T substitution
leads to disruption of the acceptor site of intron 54 and a
putative truncated protein of 2,598 aa (c.7789_7927del139/
p.Asp2597_Lys2643[LysfsX3). This splicing defect was
confirmed by RNA analysis of patient lymphoblasts
showing loss of exon 55 (Fig. 2). This mutation was
identified in only one patient.
The remaining 17 missense mutations were classified
into three categories according to the above criteria: likely
deleterious, unknown variants (UV), and likely neutral.
Six missense mutations were classified as likely delete-
rious: p.Arg250Gln, p.Gly2023Arg, p.Thr2396Ser, p.Asn
2435Lys, p.Arg2854Cys, and p.Arg3008His (Table 1). They
were considered as ‘‘likely deleterious’’ according to the A-
GVGD algorithm except for p.Thr2396Ser and p.Arg
3008His which were respectively ‘‘neutral’’ or ‘‘unclassi-
fied’’. These missense mutations were located in the FAT
Table 2 Identified ATM variants classifoed as polymorphisms in 122
BC patients with a family history of breast and haematological
malignancy
Nucleotide change Amino acid change Exon/IVS Het. freq. (%)
c.544G[C p.Val182Leu exon 8 2.0
c.2442C[A p.Asp 814Glu exon 18 1.3
c.2572T[C p.Phe858Leu exon 19 1.5
c.3161C[G p.Pro1054Arg exon 24 1.9
c.4258C[T p.Leu1420Phe exon 31 3.1
c.4578C[T p.Pro1526Pro exon 32 4.4
c.5557G[A p.Asp1853Asn exon 39 10.6
c.5558A[T p.Asp1853Val exon 39 1.1
c.1899-55T[G – IVS14 2.4
c.2125-68T[C – IVS15 3.7
c.2250?22A[C – IVS16 1.2
c.2250?34A[C – IVS16 1.2
c.2250?78G[A – IVS16 1.9
c.2839-90T[G – IVS20 38.0
c.3403-14insA – IVS25 49.0
c.3285-9del – IVS24 11.0
c.3747-34A[G – IVS27 1.0
c.3993?48A[G – IVS28 1.3
c.4777-20A[G – IVS33 1.0
c.5497-8T[C – IVS38 1.5
c.5497-15G[C – IVS38 1.0
c.8786?8A[C – IVS62 1.1
Het. freq. Heterozygote frequency according to NCBI
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protein domain and were not detected in a set of control
DNAs. They have also been previously reported in a T-PLL,
a feature that may argue in favour of their deleterious effect
as they could have been selected by the tumour process [16].
In addition, the p.Arg3008His missense mutation has been
detected in an A–T child whose second mutation was
introducing an ATM stop codon (Micol et al., in prepara-
tion). These six missense mutations were identified in six
patients.
Eleven missense mutations were classified as UV:
p.Leu651Pro, p.Ser707Pro, p.Leu752Val, p.Phe763Leu,
p.Ile826Leu, p.Val1519Ala, p.Ser1601Asn, p.Ile1659Val,
p.Ser1673Thr, p.Asn2282His, and p.Leu2307Phe (Table 1).
The majority of these UV were not located in the PI3K or
FAT domains, and the A-GVGD scores were in favour of
unclassified or neutral effect except in two cases. Regarding
the p.Leu651Pro and p.Val1519Ala missense mutations,
although their A-GVGD score was in favour of a likely
deleterious effect, they were classified as UV as their carrier
frequency amongst controls was high, respectively above 2
and 4% (Table 1). These 11 missense mutations were iden-
tified in 14 patients.
Two silent and seven intronic variants were also detected.
Only criteria (1), (2), and (5) quoted above can be used. The
in silico analyses did not suggest a splicing defect in any of
these nine variants. The frequency of the seven intronic
variants was \1% in our series of controls; they were
therefore classified as UV: IVS14, c1899-24A[G; IVS28,
c.3993?40G[A; IVS30, c.4237-54T[C; IVS31, c.4437-
7A[C; IVS48, c.6807?39C[T; IVS52, c.7516-32T[G;
IVS55, c.7927?69T[C. The p.Lys1114Lys variant was also
classified as UV, as its frequency in the control group was
\1%. The p.Leu229Leu silent variant was classified as
likely neutral, since its frequency in controls was[1%.
In summary, a total of eight patients carrying an ATM
mutation, two patients with a truncating mutation and six
patients with a likely deleterious ATM mutation, were
identified in this series of 122 patients. The frequency of
ATM heterozygote mutation carriers is 6.56% (95% CI:
2.16–10.95).
Fig. 2 cDNA analysis of the c.7789G[T mutation. a Initially
interpreted as a missense mutation, the c.7789G[T substitution is a
splicing mutation as shown by cDNA analysis of a lymphoblast cell
line established from the patient carrying this mutation. Exons 54–59
were amplified from primers located in the coding sequence
(sequence available on request). The amplified product was analysed
by 1.5% agarose gel electrophoresis. One 756 bp long fragment was
obtained from a control lymphoblast cell line; an additional fragment,
617 bp long, was detected in the c.7789G[T mutant cell line,
suggesting that exon 55 deletion has occurred. b Sequence of the 54–
59 amplified exons from the c.7789G[T mutant cell line. Superim-
position of the 54–55 and 54–56 exon junctions confirms the exon 55
deletion. The c.7789G[T substitution leads to the putative truncated
p.Asp2597_Lys2643[LysfsX3 protein
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Discussion
Epidemiological studies designed to elucidate the role of
ATM mutations in cancer risks are limited by the large size
of the gene and the large number of mutations spread
throughout the coding sequence. To simplify the extensive
laboratory work required for ATM screening, a new DNA
analysis method was applied. Using similar analysis con-
ditions for each amplicon, all of the 49 different control
mutations previously identified by direct sequencing in
Fig. 3 Family history of the eight patients carrying a deleterious or likely deleterious ATM mutation. The BC women tested for ATM mutation
are indicated by an arrow. ALL: acute lymphoid leukaemia
450 Breast Cancer Res Treat (2010) 119:443–452
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A–T children and a large gene deletion were detected by
EMMA. Multiplex analysis including the search for LGR
allowed screening of the 10 kb ATM coding sequence in
3 weeks in a large set of 94 patients.
In the series of 122 BC women with a relative with
haematological malignancy, two deleterious mutations,
leading to a putative truncated protein were identified, a
nonsense mutation, and a splicing mutation not previously
reported and characterised. The remaining 17 missense
mutations were classified into three categories: six likely
deleterious mutations, nine mutations of unknown signifi-
cance, and two likely neutral mutations. The main criterion
used to classify these missense mutations was the A-
GVGD score. Moreover, p.Gly2023Arg, p.Thr2396Ser,
and p.Arg3008His variants have been reported as somatic
events in T-PLL or B-CLL and associated with loss of the
second ATM allele by 11q deletion, features that argue
strongly in favour of their deleterious effect as they could
have been selected by the tumour process [16, 33]. The
multiplicity of criteria to assess the significance of the
functional effect of a DNA variant underlines that none a
criterion alone is sufficient and that they have to be alto-
gether taken into account with in some cases when they are
leading to divergent conclusions the need to make some
arbitrary decisions. The availability of functional testing
and in vitro functional assays allowing characterisation of
missense mutations would be very useful [7].
For each of the eight BC women carrying a deleterious
or likely deleterious ATM mutation, only one relative
presented a haematological malignancy. In six cases, this
relative was a first degree relative and in two cases a sec-
ond degree relative (Fig. 3). The disease was leukaemia in
seven cases and Kaposi sarcoma occurring at age 55 in the
remaining case. Three acute lymphoid leukaemia cases
occurred during childhood at the ages of 3, 8, and 10 years;
one leukaemia case occurred at 44 years and the three other
cases were late-onset leukaemia, occurring after the age of
80. No blood samples which would have been required for
ATM mutation co-segregation study from both cases with
haematological malignancies and with breast cancer were
obtained, most of the cases being deceased or lost of
follow-up.
The estimated frequency of A–T heterozygotes in our
series is 6.56% (95% CI: 2.16–10.95), a significantly higher
figure than that observed in the general population which is
estimated to be between 0.3 and 0.6% [12, 14]. Although a
trend towards an increased frequency of ATM carriers was
observed in our series, it was not different from that
observed in a population of familial BC women not selected
for haematological malignancy in relatives, as the fre-
quency of ATM carriers was 2.70%, a value situated in the
confidence interval 2.16–10.95 estimated in our study [14].
It is noteworthy that, although the RR of haematological
malignancies in ATM heterozygote carriers may be high—
SIR 37 in Olsen’s study—[11], the absolute risk remains
low, as the incidence of haematological malignancies is low
in the general population. Thus the availability of familial
aggregations of both breast cancer and haematological
malignancies is low, limiting the power of such study.
Finally, although the expected final classification of some
UVs in the deleterious mutation group and that of some rare
polymorphic allele will increase this frequency, a larger set
of patients with a control group of BC women with no
family history of haematological malignancy needs to be
studied to determine whether the presence of relatives with
leukaemia and/or lymphoma in BC families is a predictive
factor for ATM mutation.
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